Index

Acetylcholinesterase inhibitors, 200
Acquisition, P3M capability development after, 282–284
Action items list, 24
ACWP (actual cost of work performed), 127, 129
Added value. See also Project value management
defining, 202–203
restless legs syndrome treatment and acceptance of, 207–208
Added value drivers, 189
Administration routes, 34–35
Adverse event (AE), 158, 159, 162, 164, 166
Advertising, direct-to-consumer, 200, 201
Advisory agencies. See Payers
AE. See Adverse event (AE)
Alliances, increase in, 248
Allport, Stephen, 51, 225
Alosetron hydrochloride, 210
Alternative strategies, 182, 191–192
checklist for, 192–193
Alzheimer’s disease, determination of drug value for, 200, 214
Alzheimer’s Society, 200
Amlodipine, 74
Annual budgeting, 295
APM. See Association for Project Management (APM)
Arrowsmith, John, 225
Assessment of drug or device
NICE, 213–214
strategy development and, 187–188
Association for Project Management (APM), 5, 86, 90, 250
Body of Knowledge, 288
Assumptions, examining in risk and opportunities workshop, 142, 143
AstraZeneca, 199–200
Automation of work, small company size and, 23
Ballard, Clive, 200
BCWP (budgeted cost of work performed), 128–129
BCWS (budgeted cost of work scheduled), 127, 129
Behavior change, shift of real and imagined power and, 303
Benefit-risk assessment, 158
Benefits Delivery Criteria, 291
Benefits management, 89–90, 249, 307
Bennett, John, 50
Best in class profile, 220, 221
Best practices, 287–309
business processes, 303–304
change agents and, 306
change program and, 306
choosing practice areas to improve, 300–302
commercial arrangements, 297, 301
communicating need for change, 302–303
concept of, 287–289
defined, 288
organizational aspects, 307–308
people and organization, 298–299, 301
planning and control, 293–296, 301
P3M infrastructure, 290–291, 301
project management in drug development, 289–308
scientific integration, 296–297, 301
senior management and, 300, 302, 305
standards, 288
strategy integration, 291–293, 301
system functionality, 304–305
Biologic License Application (BLA), 113

Portfolio, Program, and Project Management in the Pharmaceutical and Biotechnology Industries, Edited by Pete Harpum
Copyright © 2010 John Wiley & Sons, Inc.

313
Biologics
administration of, 34–35
manufacturing and controls for, 34

Biotechnology companies
drug development in small and start-up, 33–46
portfolio management challenges for, 11–12

BLA. See Biologic License Application (BLA)

Blockbuster model, 102

Board on Population Health and Public Health Practice, 167

Bodies of Knowledge (BoKs), 103–104

BoneStrong TPP, 114


Brand management. See Program management
Brand programs, 54
Brown, Trevor, 51

Budgeting
annual, 295
project, 120–121, 295
Budget software, 126
Buffer management, 132
Build/buy decision, 272
Bulk drug production, 78

Bureau de Transparence, 199, 204, 213
value-based pricing and, 215, 216

Business case, drug safety risk management and, 169–170
Business case and benefits management plan, 307
Business planning cycle, 179–180
Business processes, 303–304
Business process integration, 227–238
benefits of, 238
capacity management process, 230
financial, 230–231
portfolio management process, 229
project management information system, 231–233
project management process, 229–230
reporting, 233–238
Business strategies, functions of, 108
Business unit strategy, 177

Calhoun, A. S., 163
Candidate nomination, score table example, 146
Capacity management, 43–46
architecture of full system, 46
generic process, 44
in integrated business process, 228, 230
Capacity reports, 235, 236, 237
Carers, drug value and, 201
Cash flow curve, 120
CATS (Cross-Application Time entry System), 231
CBS. See Cost breakdown structure (CBS)
CCUs. See Critical Care Units (CCUs)
CDER. See Center for Drug Evaluation and Research (CDER)
Celgene, 217
Center for Drug Evaluation and Research (CDER), 167
Center for Post-Market Drug Evaluation and Research, 163–164
Centre for Medicines Research (CMR), 59, 243
Certain uncertainty, 120

Change
behavior, associated with shift of real and imagined power, 303
of business processes, 303–304
communicating need for, 302–303
role and responsibility redefinition and, 304
strategic actions and, 180
system functionality and, 304–305
Change agents, 306
Change control, 105
best practices, 294
Change management intervention, 300
Change manager, 307
Change programs
factors leading to successful, 305–308
robust, 306
senior management and, 305
structure of, 307
Checklist for alternative strategy contents, 192–193
Chronic conditions, compliance for, 210
Chronic obstructive pulmonary disease (COPD), program approach to successive medicine brands, 87, 88
Churchill, Winston, 163
Cimetidine, 199
Classic strategy model, 184, 185
**Clinical evaluation process, contract research organizations and**, 16–17
**Clinical research services**, 219
**Clinical trials**, 78, 158–159
drug price and design of, 217–218
location worldwide, 219
phases, 159–162
transition from research to drug development and, 34
value-directed project management and, 220–221
**CMMI Development Version 1.2**, 288
**CMR. See Centre for Medicines Research (CMR)**
**Commercial arrangements, best practices**, 297, 301
**Commercial value, measuring**, 189, 190
**Commercial value assuming success**, measuring, 80
**Communication**
inadequate, 6–7
malleable channels of, 23
organizational size and, 23–24, 31
of uncertainty, 151–153
**Compliance**
with medications for chronic conditions, 210
project success and, 29
**Composition of matter patent**, 60
**Concept design decision gate**, 112
**Conceptual design**, 112
**Configuration management**, 123, 296–297
**Conflict management**, 299
**Constipation-predominant irritable bowel syndrome**, 211
**Constraints, theory of**, 130
**Consumer value**, 198
**Contingency plan, risk**, 150–151
**Contingent actions, uncertainty management and**, 139
**Contract research organizations (CROs)**, 3
portfolio management for, 12
project management at, 14–17
project manager roles at, 14–15
selecting, 22
**Control account**, 116
**Control action**, 124–125
**Control best practices**, 293–296, 301
**Control device, business strategy as**, 108
**Control processes**, 55, 56, 107–125
budgeting, 120–121
control action, 124–125
defining deliverables, 110–115
defining plan of events, 118–119
defining project objectives, 108–109
defining work packages, 115–117
estimating work, 117–118
key performance indicators (KPIs), 121–122
performance measurement, 124–125
planning project, 109–125
schedule and, 120–121
scheduling work packages, 118–120
scope change control, 122–124
strategic plans and, 180
**Cook-Davies, Terry**, 225
**COPD. See Chronic obstructive pulmonary disease (COPD)**
**Core competencies, building, to reduce risk**, 13–14
**Corporate culture, communication of strategy and**, 177–178
**Corporate scenarios**, 181
**Corporate social responsibility (CSR) statements**, 195
**Corporate strategy**, 56, 177, 185
bridging gap from to candidate plans, 62–82
drug project strategy and, 291
**Cost. See also Development cost**
balancing against benefit for P3M control systems, 264
of changes on project, 122, 123
development, measuring, 80, 81
drug safety risk management, 156, 164
estimating work package, 117–118
fully absorbed to defined point, 81
in iron triangle, 75, 105
as measure of project success, 29
of new chemical entity, 59
of New Drug Application, 263
project management at contract research organizations and, 16
in project objective, 109
value-directed project management and, 220
**Cost breakdown structure (CBS)**, 118
**Cost forecast**, 120
**Cost performance index (CPI)**, 129
Cost trade-off, justifying price of new treatment based on, 217
CPI. See Cost performance index (CPI)
Cranfield School of Management and Premark Services, 243
Critical Care Units (CCUs), as integrated organizations, 239–240
Critical chain scheduling, 125–126, 130–132
Critical path, 118
prioritization and, 252
Critical Path Initiative, 228
Critical Success Factors (CSFs), 291
CROs. See Contract research organizations (CROs)
Cross-functional drug development, 227–238
CSFs. See Critical Success Factors (CSFs)
CSR. See Corporate social responsibility (CSR) statements
Cultural change, uncertainty management and, 293
Customer value, maximizing in drug development, 218–222
Cycle times, reduction of, 228
Database mining, 165, 166
Data mart approach, 280
Data repository approach, 280
DDLC. See Drug development life cycle (DDLC)
Decision-generated risk, 29–30
Decision making
authority for each management layer, 91
drug development, 39–40
life-cycle management and, 240–241
matrix environment and, 39
organizational size and, 29–31
stage-gate, 184, 185, 193–194
Deliberate strategy, 177
Deliverables
defining, 110–115
ease of change to, 122
Deliverables breakdown structure, 115
Delivery, reducing gap between needs and, 68
Department of Health and Human Services, 167
Descriptive strategic thinking, 196
Design authority, 307
Desire to use a drug, 205
Detailed specification, 113
Developing and Use of Risk Minimization Action Plans, 166
Development cost
measuring remaining, 80
measuring risk-adjusted fully absorbed remaining, 81
Development projects (DPs), 13
Development time, planning and, 8
Device assessment, strategy development and, 187–188
Diarrhea-predominant irritable bowel syndrome, 210–211
Direct-to-consumer (DTC) advertising, 200, 201
Do-ability, measuring, 81
Doctors, perception of drug value, 201, 202, 204–208
Documentation review, strategy development and, 189
Donepezil, 200
Dopamine agonists, 207
DPs. See Development projects (DPs)
Drug, consumer choice of, 200–202
Drug assessment
NICE, 213–214
strategy development and, 187–188
Drug buying process, preference within, 202–203
Drug development. See also Life sciences new product development projects;
New product development
capacity management, 43–46
clinical trial design and drug price, 217–218
cross-functional, 227–238
decision making and, 39–40
high cost of, 33–34
integrated (See Integrated drug development)
managing pipeline of new drugs, 37–39
maximizing customer value and, 218–222
organizational leadership and, 33–36
program management in, 85–99
project management of, defining role and value of, 40–43
transition from research to development, 34–35
Drug development core team, 28
Drug development life cycle (DDLC), 292
early stage opportunities, 241–242
integration across functions and geographical boundaries, 244–248
project life cycle and, 290
value and risk and, 240–243
Drug development organizations
development of P3M capability in, 259–284
implementing P3M best practices in (See Best practices)
Drug development phases, 159–162
phase I, 160
phase II, 160–161
phase III, 160, 161
phase IV, 160, 161–162
Drug formulation development, 78
Drug profiles, 73
Drug program, 55
Drug safety, 54, 136
defined, 158
guidance documents, 166
history of, 162–163
laws, 162, 163
leadership in, 171, 172
post-approval assessment studies, 172
Drug safety data, 172
Drug safety risk, 51
Drug safety risk management, 155–173
clinical trials, 158–159
drug development phases, 159–162
effect on functional activities, 172
factors affecting successful, 169–171
historical lessons, 162–163
International Conference on Harmonization, 158
preparing for the future, 171–172
product risk, 156–157
recent regulatory developments, 167–168
regulatory influences, 163–167
strategic leverage of, 170–171
Drug safety withdrawals, 156–157, 165–166
Drug value, 199–200
health-care providers’ perception of, 204–208
price and, 25–218
stakeholders’ perception of, 203–215
Drug value management, 292
Drug Watch website, 166
Dry eye, 212–213
DTC. See Direct-to-consumer (DTC) advertising
Dunson, Thomas R., 2, 50
Early stage projects (ESPs), 13
Earned value analysis (EVA), 125, 127–130
Earned value curve, 128
Earned value management (EVM), 49, 221
E2E Pharmacovigilance Planning, 166
Efficacy, new product development failure and, 7
Efficient risk horizon modeling, 153
EIS. See Enterprise Information Standards (EIS)
Ekbom, Karl, 207
Elixir Sulfanilamide, 163
EMEA. See European Medicines Agency (EMEA)
Emergent strategy, 177
Engineering design, 4
eNPV. See Expected net present value (eNPV)
Enterprise Information Standards (EIS), 279–280
Enterprise project management (EPM), 28
Enterprise Project Management software, 97
Enterprise project management tools, 97
Enterprise resource planning (ERP), 231, 232
Enterprise-wide P3M software systems, 278–279
outsourcing supplier selection criteria, 280–281
success criteria, 282
Entrepreneurial mind-set, 22–23
Environmental scan, 186–187
EPM. See Enterprise project management (EPM)
ERP. See Enterprise resource planning (ERP)
Esomeprazole, 199
ESPs. See Early stage projects (ESPs)
Estimating
best practices, 293–294
three-point, 118
work packages, 117–118
European Medicines Agency (EMEA), 161, 166, 167
EVA. See Earned value analysis (EVA)
EVM. See Earned value management (EVM)
Executive sponsor, in integrated organization, 256
Expected net present value (eNPV), 190
Expert advisors, doctors as, 205, 206
External barriers, reshaping in integrated organization, 255
External projects, 4
Extrinsic preference
drug buying process and, 202–203
perception of drug value and, 207
Family, drug value and, 201
FDA. See Food and Drug Administration (FDA)
FDA “Drug Watch” for Emerging Drug Safety Information, 166
FEL. See Front-end loading (FEL)
Fen-Phen-related damage, 157
Financial forecast report, 233
Financial management, in integrated business process, 228, 230–231
Financial reports, 236–238
Financial return, customer value measures and, 240
Fisher, Inge, 225
Five Forces Model, 179
5-HT3 antagonist, 210
5-HT4-receptor agonist, 211
Focusing steps, 130
Food, Drug, and Cosmetic Act of 1938, 162, 163
Food and Drug Administration (FDA)
clinical trials and, 161, 162
Critical Path Initiative, 228
drug safety and, 163, 164
Drug Watch website, 166
guidelines on transition from research to drug development, 34
guidelines regulating marketing authorization, 16
harmonization with EMEA initiatives, 167
new drug applications to, 85
new molecular entity drugs approved, 227
recent regulatory developments, 167–168
Food and Drug Administration Safety Act of 2005, 163
Food and Drugs Act of 1906, 162
Ford Edsel, 197
Front-end loading (FEL), 292
FTEs. See Full-time equivalents (FTEs)
Full-time equivalents (FTEs), 231
Functional drug project, 55
Functional lines, P3M capability and, 268
Functional matrix, 245–248
Functions
integration mechanisms between projects and, 298
reshaping barriers between, 254–255
The Future of Drug Safety, 167
Galantamine, 200
Gantt chart, 119
Gap analysis, 308
Gastro-oesophageal reflux disease (GORD), 199, 201
General Electric, 254
Geographical barriers, reshaping in integrated organization, 255
GERD. See Gastro-oesophageal reflux disease (GORD)
Glaxo, 216
GlaxoWellcome, 210
Globalization, 255
Goals
alignment of project and functional, 299
project types and, 4
Goals and methods matrix, 4
Gold standard products, 73
Good Pharmacovigilance Practices and Pharmacoepidemiology Assessment, 166
GORD. See Gastro-oesophageal reflux disease (GORD)
Governance
best practice for P3M, 290
change program and, 307
of drug development cycle, 251–252
drug safety governance standards, 171–172
program, 89–92
risk in pharmaceutical portfolio and, 71
Governance bodies for portfolio and project oversight, 40
GPIIb/IIa inhibitors, 202
Grogan, Pat, 225

H2 antagonists, 217
Harpum, Pete, 50, 51, 225
Health, safety, and environmental management, 49
Health-care providers, perception of drug value, 201, 202, 204–208
Healthcare Research and Quality, 199
Health Technology Assessment (HTA), 214, 215. See also Payers
Heavyweight team model, 246–248
High people core competence, 273
High process core competence, 274
High system core competence, 275
Horizontal boundaries, reshaping in integrated organization, 254–255
H2-receptor antagonists, 199
HTA. See Health Technology Assessment (HTA)
Human Resource department information, strategy development and, 189
Hynes, Marty, 225

IBS. See Irritable bowel syndrome (IBS)
ICH. See International Conference on Harmonization (ICH)
ICT. See Information and Communication Technology (ICT) sector
Imigran, 199
Impact score tables, 146–147
Individual competence, 298
Informatics, 275
Information and Communication Technology (ICT) sector, 28
Information management, 297
Information technology systems capacity management, 44–46
project management, 231–233
In-licensing, increase in, 248
Innovation-adoption model, 205
Institute of Medicine, 167
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG), 204, 213
Integrated business process. See Business process integration
Integrated drug development, 239–257
future of, 257
implications of integration, 253–255
integration across functions and geographical boundaries, 244–248
life-cycle management, 240–244
strategy, portfolio, program, and project alignment, 248–253
working in integrated organization, 256–257
Integrated organization implications of, 253–255
working in, 256–257
Intellectual Property (IP) issues, identification of, 296–297
Intellectual property position, project management and, 38
Interface control, 123
Internal capability, risk in pharmaceutical portfolio and, 70
Internal projects, 4
Internal rate of return (IRR), 190
International Conference on Harmonization (ICH), 16, 158
International Conference on Harmonization of Technical Requirements for Registration of Life sciences for Human Use, 166
International Project Management Association (IPMA), 250
Interventional cardiology, 217
Interviews with functional experts, strategy development and, 188–189
Intrinsic preference
drug buying process and, 202, 203
perception of drug value and, 207
Investment, balancing risk and, 75–79
Investor value, 198
IP. See Intellectual Property (IP)
IPMA. See International Project Management Association (IPMA)
IQWiG. See Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
Iron triangle, 75, 105, 191
IRR. See Internal rate of return (IRR)
Irritable bowel syndrome (IBS), 210–211

Jamieson, Ashley, 225
Job descriptions, 43

Key performance indicators (KPIs), 121–122, 291
Killer experiments, 192
Knowledge areas, project management, 5
Knowledge management, 293
KPIs. See Key performance indicators (KPIs)

Lafl ey, A. G., 242
Large organizations
decision making in, 29–30
management focus of attention and, 22
P3M capability and, 269–270
portfolio management and, 10–11
project management advantages of, 32
project management capability and, 7–8
project meetings and, 24

Launch
date of first, 81
timing of, 77

Launch/Phase IV impact score table, 147

Laws, drug safety
FDA Safety Act of 2005, 163
Food, Drug, and Cosmetic Act of 1938, 162
Food and Drugs Act of 1906, 162
L-dopa, 207

Leadership. See also Project leader/leadership
attributes, 36
in drug development, 33–36
drug safety, 171, 172
project management at contract research organizations and, 15
project management to support challenges of, 35–36

Licensing compounds, 67
Life-cycle management, 240–244
Life science organizations
developing project control methods in, 105–107
portfolio management in, 10–12

Life science product safety. See Drug safety risk management
Life sciences
consolidation of industry, 260, 261
decreased productivity pre dollar invested, 260
drivers to develop integrated P3M in, 260–263
sources of uncertainty in new product development projects, 140
uncertainty management in (See Uncertainty management)
Life sciences new product development projects, 6–10
building core competencies to reduce risk, 13–14
differences between life sciences and other sectors’ project management capability, 7–8
issues facing, 6–7
managing value in, 12–13
portfolio management and, 10–12
project management at contract research organizations and, 14–17
project manager role in, 9–10
project planning considerations and, 8
uncertainty in R&D projects and, 9

Lightweight team model, 246–248
Line management, outline responsibilities, 251

Linna, Susan, 2
Lloyd, William Forster, 253
LOE. See Loss of exclusivity (LOE)
Losec, 199
Loss of exclusivity (LOE), 277
Low-cost at-risk plan, 78
Low people core competence, 273
Low process core competence, 274
Low system core competence, 274

Managed care organizations. See Payers
Management. See also Senior management
focus of attention, 22
outline responsibilities for, 251
responsibilities in program, 94–96
Management-level P3M, matching to operational-level, 271–275
Management process groups, 5
Managerial processes, 304
Marketing, relation to R&D, 244
Marketing theory, applied to pharmaceutical products, 205
Market opportunity, 189
Massachusetts Institute of Technology, 162
Matrix structure, 25, 26
decision making in, 39
Maturity models, 250–251, 257, 288, 308
Me-better status, 220, 221
Medical device projects. See Life sciences
new product development projects
Medical devices, scope definition for,
111–113
Medical device safety, 155
Medical need, measuring, 80
Medium-sized organizations
P&M capability and, 267–268
portfolio management and, 11
project management capability and, 8
Meetings, small organizations and, 23
Megaproject, 86–87
Merck, 157, 165
Mergers, to boost development portfolio, 67
Microenvironmental factors, of
environmental scan, 186–187
Microsoft, 97, 231
Middle management, achieving best
practice and, 302
Mind-set, entrepreneurial vs. large and
established, 22–23
Mission statement, 194
Mitigation plan, risk, 150–151
Monte Carlo analysis, 97–98, 153
Moore, Bob, 225
Morfin, Eric, 2, 50
Multi-project repository systems, 278
Narcolepsy, stakeholder perception of effect
of, 208–210
National Aeronautics and Space
Administration Man on the Moon
project, 86
National Commission for the Rational Use
of Medicines, 213
National Health Service (NHS), 200
National Health (U.S. health insurer),
199
National Institute for Clinical Excellence
(NICE), 203, 204
acetylcholinesterase inhibitors for
Alzheimer’s disease and, 200
assessment process, 213–214
drive to manage drug cost, 60
Revlimid and, 217
value-based pricing and, 215
NCE. See New chemical entity (NCE)
NDA. See New Drug Application (NDA)
Needs. See Organizational needs; Patient
needs
Negotiation, 299
Net present value (NPV), 190, 231
estimating value and, 73
expected, 190
link to value measures, 240
measuring, 80
Net present value (NPV) analysis, 38
Net present value (NPV) capital budgeting,
13
New chemical entity (NCE)
cost of, 59
time to develop, 60
New Drug Application (NDA), 85, 113,
263
New molecular entities (NMEs), number
approved annually, 227
New product development. See also under
Drug development
description of unmet need and, 216
sources of uncertainty in, 140
strategy development process, 183, 184
Nexium, 199–200, 201
NHS. See National Health Service (NHS)
NICE. See National Institute for Clinical
Excellence (NICE)
NMEs. See New molecular entities (NMEs)
Nopane (pseudonym), 157
Novartis, 210
NPV. See under Net present value (NPV)
Objectives
stage-gate, 193
strategic, 190–191
OBS. See Organizational breakdown
structure (OBS)
Observational studies, 165
Office of Government Commerce (OGC),
288
Office Project (software), 231, 232
Offshoring, 219
OGC. See Office of Government Commerce (OGC)
Ohmae, Kenichi, 203–204, 211, 218
OLAP. See Online analytical processing (OLAP)
Omeprazole, 199
“One best way,” 287
Online analytical processing (OLAP), 278
Open architecture strategy, 280
Operational-level P3M capability, matching to management-level, 271–275
OPM3. See Organizational Project Management Maturity Model (OPM3)
Opportunity(ies)
assessment of risk and, 138–139
assigning owners of, 148
defined, 137
identifying, 141–143
planning for, 148–150
scoring and prioritizing, 143–148
Opportunity maximization plan, 149
Opportunity realization plan, 149–150
Opportunity score, 147
Options
scenarios and, 181, 182
strategic, 182
OPX2 software, 97
Organization, project, 110–118
defining deliverables, 110–115
defining work packages, 115–117
estimating work, 117–118
Organizational breakdown structure (OBS), 116–117, 118
Organizational capability, 296
strategy development and, 188–189
Organizational context, for portfolio, program, and project management, 290
Organizational culture, 21–24
power of stakeholders groups and, 26
Organizational memory, risk reduction and, 14
Organizational needs
P3M capability and, 275–276
project management and, 35
reducing gap between delivery and, 68
Organizational Project Management Maturity Model (OPM3), 250–251, 257, 288
Organizational size
communication and, 23–24
decision making and, 29–31
entrepreneurial vs. large and established mind-set and, 22–23
impact on drug project management, 21–32
management focus of attention and, 22
organizational structure and, 25–27
portfolio management and, 10–11
prioritizing projects and, 24–25
project leadership and, 27–29, 32
project management capability and, 7–8
scaling P3M capability to match, 264–270
Organizational structure, 25–27
Organizational values, program strategies and, 194–195
Organizational vision, 194
Organization best practices, 298–299, 301
Outsourcing, 219
supplier selection criteria, 280–281
Oversight, 41–42
Paper war, 16
Parkinson’s disease, compliance with timing of medications, 210
Patent
composition of matter, 60
expiration of, 60
Patient groups, role in product reimbursement, 200, 214, 217
Patient needs
defined, 210
measuring, 80
new product development and description of unmet, 216
regulator and, 211–212
responding to, 210–213
Patient registries, 165
Patients, perception of drug value and, 200–202, 208–213
Payback period, 190
Payers, drug value and demonstrating, 216–217
perception of, 201, 202, 213–215
PBS. See Product breakdown structure (PBS)
People
allocation of, 28
best practices, 298–299, 301
individual competence, 298
P3M capability and, 263, 265, 272, 273, 276, 281, 283
program management and, 88–89
Performance evaluation and review, 118
Performance management, best practices, 295–296
Performance measurement, 124–125
Performance measurement baseline (PMB), 121
Performance specification, 112
PESTLE analysis, 179, 181, 186
Pfizer, 217
Pharmaceutical Benchmark Forum, 59
Pharmaceutical companies
consolidation of, 260, 261
evolution of P3M capability in, 262
project management capability and, 8
Pharmacovigilance, 158
Phase I impact score table, 146
Phase I trials, 160
Phase II impact score table, 147
Phase II trials, 160–161
Phase III impact score table, 147
Phase III trials, 160, 161
Phase IV trials, 160, 161–162, 165
PIG. See Probability impact grid (PIG)
Plan by project report, 233, 234
Planisware’s OPX2, 97
Planning
best practices, 293–296, 301
change, 307–308
drug safety risk management, 169
in life science projects, 8
for opportunity, 148–150
program, 88–90
for risk, 150–151
rolling wave, 8
Planning, project, 109–124
budgeting, 120–121
impact of poor, 109
key performance indicators, 121–122
organization, 110–118
scheduling, 118–120
scope change control, 122–124
Planning horizon, 229–230
Planning packages, 115–116
Plan of events, defining, 118–119
Plan vs. actual spending report, 233, 234
PMB. See Performance measurement baseline (PMB)
PMI. See Project Management Institute (PMI)
PMIS. See Project Management Information System (PMIS)
PMO. See Program management office (PMO)
POC. See Proof of concept (POC)
Portfolio
composition of, 70
defined, 54
Portfolio, program, and project control processes, relationships among, 104
Portfolio, program, and project management (P3M)
best practices (See Best practices)
definitions, 53–54
infrastructure, 290–291, 301
organizational vision for, 265–266
overview, 53–57
process integration, 57
relationship between processes, 55–56
Portfolio, program, and project management (P3M) capability, 259–284
case studies, 276–277, 282–284
competencies to achieve capability, 270–277
developing and implementing, 277–284
managing tension between current operations and future capability, 263–264
scaling capability to match organizational size, 264–270
strategic drivers to develop, 260–263
Portfolio, Programme, and Project Management Maturity Model, 288
Portfolio delivery, 250
Portfolio design, 250
Portfolio management, 57, 59–83. See also under Portfolio, program, and project management (P3M)
best practice, 290–291
bridging the gap from corporate strategy to candidate plans, 62–82
defined, 248–249
Portfolio management (cont’d)
determining what current portfolio delivers, 63–65
determining what portfolio needs to deliver, 63
developing portfolio operational or implementation plan, 67–82
in integrated business process, 228, 229
integration of functions, 246
in life science organizations, 10–12
linkage between projects, 65
matching to company strategy, 61–62
matching what is needed to what might be delivered, 65–67
maturity of, 70
organizational size and, 25
outline responsibilities, 251
overview, 59–60
PMI standards, 257
process, 250
Portfolio operational plan, 67–82
assessing and managing value, 72–75
balancing risk and investment, 75–79
building portfolio resource demand picture, 69–72
pharmaceutical portfolio risks, 70–71
portfolio priorities, 79–82
portfolio risk management, 69
Portfolio priorities, 79–82
in project management information system, 231
Portfolio reports, 233–235
Portfolio risk management, 69
Portfolio rules, 38
Portfolio strategy, 56, 185
Portfolio uncertainty management, 55
Post-marketing commitment creep, 167
Powell, Martin, 50
Power
organizational culture and, 26
shift of real and imagined, 303
PPIs. See Proton pump inhibitors (PPIs)
Precedence diagramming, 118
Preclinical studies, 160, 164
Preference
extrinsic, 202–203, 207
intrinsic, 202, 203, 207
Premarketing Risk Assessment, 166
Prescriptive strategic thinking, 196
Pricing, value-based, 215–218
Primavera software, 97
Prioritization
project, 24–25, 79–82, 250, 252–253
strategic planning and, 180
Probability impact grid (PIG), 147–148
Probability impact matrix, 152
Probability of successful launch, measuring, 80
Probability score table, risks and opportunities and, 143, 146
Process
P3M capability and, 263, 266, 272, 274, 276, 281, 283
program management, 89–90
Process integration, 56, 57
Proctor and Gamble, 242
Procurement, 297
Product, 110. See also Deliverables
gold standard, 73
Product breakdown structure (PBS), 115, 118
Product development, 4. See also under
Drug development; New product development
Product development programs, 180
Product failures, examples of, 197
Productivity
of equipment, 120
of people, 120
of resources, 120
Productivity index
measuring, 81
risk-adjusted, 81
Product life cycle, 241
Product line extensions, 85
Product pipeline
managing new drug, 37–39
vision of, 35–36
Product profile and scope, 73, 76, 244
Product quality, product development and, 106
Product risk, 156–157
Product safety, 155
Product uncertainty (drug safety), 54, 55, 136
Product value, factors with potential to impact, 76–77
Profiles, drug, 73, 76, 244
Program
brand, 54
defined, 6, 54, 86–88
origination of, from strategy, 180, 181
planning, 88–90
projects in, 249
sponsorship of, 88–89
Program charters, 94–96
team, 95, 96
Program governance, 89–92
hierarchical relationship between levels, 90
Program management, 50, 65. See also under Portfolio, program, and project management (P’M)
business change and, 249
definition of program, 86–88
in drug development, 85–99
evolution of, 87, 88
low complexity structure, 93
outline responsibilities, 251
PMI standards, 257
program charters and management responsibilities, 94–96
program governance, 90–92
program planning, 88–90
program structure, 90–92
project management vs., 88
risk management, 92–94
standards for, 249
tools, 97–98
Program management office (PMO), 90
Program manager, 90
change and, 307
RACI diagram and, 95
risk management and, 94
role requirements, 88, 89
Program risk management, 92–94
Program scope, development of, over time, 87
Program steering committee, 90–91
Program strategy, 56, 175–196
approved strategy to next phase, 195
business planning cycle, 179–181
corporate or portfolio strategy, 185
creation of alternative strategies, 190–193
definitions of strategy, 176–178
development process, 184–195
drug or device assessment, 187–188
environmental scan, 186–187
introduction, 175–176
models for developing, 178–179
organizational capabilities, 188–189
organizational values and, 194–195
overview, 176–182
resource analysis, 186
scenarios within which programs develop strategic options, 181–182
social responsibility and, 195
stage-gate decision making, 193–194
timing for development of, 183
value propositions, 189–190
Program structure, 90–92
Program uncertainty, 54, 55
Project, 3–6
accelerating, 66
boundaries of, 103
defined, 3, 54
defining objectives, 108–109
external, 4
increasing value of projects in development, 66
integration mechanisms between functions and, 298
internal, 4
life sciences new product development, 6–10
linkage between, 65
prioritizing, 24–25
scheduling (See Scheduling, project)
sponsorship of, 88–89
stages of, 4–5
Project and functional goal alignment, 299
Project budgeting, 120–121
best practices, 295
Project charter, 249
Project control, 50, 101–133
budgeting, 120–121
business-as-usual management control vs., 102
context of, 103
control processes, 103, 104, 107–125
critical chain scheduling, 130–132
defined, 101
defining deliverables, 110–115
defining project objectives, 108–109
defining work packages, 115–117
Project control (cont’d)
  developing in life science organizations, 105–107
drug development, 106–107
earned value analysis (EVA), 127–130
enhancing, 125–132
estimating work, 117–118
introduction to, 101–102
key performance indicators (KPIs), 121–122
organizational strategy for, 106
overview, 102–105
performance measurement and control
  action, 124–125
  planning project, 109–124
  plan of events, 118–119
  scheduling work packages, 118–120
scope change control, 122–124
software, 126–127
Project data, integration of, 296
Project demand vs. supply report, 234–235
Project development projects, in life
  sciences, 6–10
Project governance, in integrated
  organization, 256, 257
Projectization, 245
Project leader/leadership, 27–29. See also
  Project manager
  attributes, 27–28, 32, 36
  responsibilities, 28
Project life cycle, drug development life
  cycle and, 290
Project management, 3–6, 249–250. See also under Portfolio, program, and
  project management (P3M)
  best practices, 300–308
  capability, 7–8
  at contract research organizations, 14–17
defined, 6
defining role and value of, 40–43
drug, 21–32
expectations of role, 41–42
information system, 231–233
in integrated business process, 228, 229–230
in integrated organization, 250
knowledge areas, 5
leadership attributes, 27–28, 32, 36
models, 245
organizational size and, 21–32
outline responsibilities, 251
prioritizing projects, 24–25
program management vs., 88
recruiting and interviewing process and, 36
support for fast, effective decision making, 39–40
to support leadership challenges, 35–36
support to meet challenges of unstable
  product pipeline, 38–39
uncertainty and (See Uncertainty
  management)
value-directed, 219–221
“Project Management Best Practice in the
  Life Sciences,” 287
Project Management Information System
  (PMIS), 231
reporting, 233–238
Project Management Institute (PMI), 5, 250
Organizational Project Management
  Maturity Model (OPM3), 288
Pharmaceutical Special Interest Group,
  9–10
  Standard for Program Management, 89
Project management office (PMO), 42
Project management process analysis,
  15–16
Project management standards, 308
Project manager, 27
  in contract research organizations, 14–15
  in integrated organization, 256, 257
  lack of authority given, 245
  leadership responsibilities, 28
  performance information reporting and, 125
  role in life sciences new product
devvelopment projects, 9–10
  role requirements, 88, 89
  in small organizations, 23
Project meetings, 23–24
Project performance measurement, 124–125
Project plan, 103, 235–236
baselining, 124–125
Project prioritization, 250, 252–253, 278
Project reports, 235
Project scope
  capacity management and, 230
  value-directed project management and,
  220
Project strategy articulation of, 292
corporate strategy and, 291
Project success measures, 29
Project teams, 9
charter, 95, 96
globally distributed, 248
in integrated organization, 256, 257
integration and, 246–247, 253
structure and roles, 298
transferring experience/know-how, 14
Project triumvirate, 109
Project uncertainty, 54, 55, 136
Project value management, 197–223
defining “added value,” 202–203
how value is delivered, 198
maximizing customer value, 218–222
price and, 215–218
product failures, 197
stakeholders’ perceptions of value, 203–215
value creation, 199–203
Proof of concept (POC), 78
Proprietary Project Management assessment tools, 288
Proton pump inhibitors (PPIs), 199
P³M. See under Portfolio, program, and project management (P³M)
Pure project environment, 26
QALY. See Quality adjusted life years (QALY)
Quality adjusted life years (QALY), 200, 214
Quality of life, perception of drug value and, 208
Quantitative analysis, 153
Quantitative approach to project prioritization, 79–82
Quantitative risk analysis techniques, 97
RACI. See Responsibility/accountability/consulted/informed (RACI) diagram
Ranitidine, 199
Rare events, 159
Rate of return, internal, 190
Recruiting process, project management and, 36
Reference case, 213
Regulatory developments, recent, 167–168
Regulatory influences, on drug safety risk management, 163–167
Regulatory processes, contract research organizations and, 16
Regulatory risks, 76
Reimbursement agencies. See Payers
Remaining development cost, measuring, 80
Reporting/reports
capacity reports, 236
financial reports, 236–238
portfolio, 233–235
project management information system, 233–238
project plans, 235–236
Requirements definition, 111–112
Requirements management, 49
Research, transition to drug development from, 34–35
Research and development
increase in spending, 227
innovative commercial, 204
managing, 37
marketing and, 244
in P³M structure, 56
portfolio management, 11
uncertainty in project, 9
Research and development budget, product line extensions and, 85
Research and organizational design, 4
Resource allocation, 28, 119–120
Resource analysis, 186
Resource forecasting, 233
Resource management, 28–29, 105, 119–120
best practices, 295
Resource profile, 119
Resources
drug safety risk management and alignment of, 170
impact of change on needs, 253
insufficient project, 6
Respiratory brand management, 87, 88
Responsibility
decision-making, 39–40
redefining, 304
Responsibility/accountability/consulted/informed (RACI) diagram, 95, 117, 298
Responsibility assignment matrix, 116–117
Restless legs syndrome (RLS), 207–208, 216
Return on investment, link to value measures, 240
Revenue
annual drug, 60
pressure to generate quickly, 37
Revenue growth rates, 61–62
Revenue recognition, portfolio management and, 12
Revlimid, 217
Rhabdomyolysis, 159
Risk. See also Drug safety risk
adoption of new drug and, 205–206
assessment of opportunity and, 138–139
assign owners of, 148
balancing investment and, 75–79
building core competencies to reduce, 13–14
decision-generated, 29–30
defined, 137, 206
identifying, 141–143
in iron triangle, 75, 105
for pharmaceutical portfolio, 70–71
planning for, 150–151
portfolio risk management, 69
regulatory, 76
scoring and prioritizing, 143–148
technical, 76
uncertainty vs., 137
Risk-adjusted fully absorbed remaining development cost, measuring, 81
Risk adjusted NPV, measuring, 80
Risk-adjusted productivity index, measuring, 81
Risk analysis, quantitative techniques, 97
Risk-benefit ratio, perception of drug value and, 205–206
Risk contingency plan, 150, 151
Risk escalation process, 94
Risk management, 5. See also Drug safety risk management; Uncertainty management program, 92–94
Risk mitigation strategies, 150–151
Risk option weighting, 153
Risk profile, monitoring ongoing, 151
Risk score, 147
Risk to benefit profile, 164
Rivastigmine, 200
RLS. See Restless legs syndrome (RLS)
Rofecoxib, 165–166
Rogers, Everett, 205
ROI assessments, 278
Roles, redefining, 304
Rolling wave planning, 8
Roosevelt, Franklin, Jr., 162
Sarbanes-Oxley Act, 42
Scale of effort rating, 300–301
Scenario planning, 278
Scenarios
corporate, 181
options and, 181, 182
within which strategic options develop, 181–182
Schedule
control process and, 120–121
as measure of project success, 29
Schedule performance index (SPI), 129
Scheduling, project, 118–120
best practices, 294
critical chain, 125–126, 130–132
plan of events, 118–119
resource, 119–120
work package, 118–119
Scientific expertise, insufficient, 7
Scientific integration, best practices, 296–297, 301
Scope
in iron triangle, 75, 105
in project objective, 108, 109
Scope change control, 122–124
Scope definition for medical devices, 111–113
Scope management, 90
best practices, 293
Scope statement, 30
Scottish Medicines Consortium (SMC), 203
S.E. Massengill Co., 163
SEI. See Software Engineering Institute (SEI)
Senior management
achieving best practice and, 300, 302, 305
agenda in integrated organization, 256–257
outline responsibilities, 251
P3M capability and, 268, 271–272
Sensitivity analysis, 221–222
Seretide, 87, 88
Shakeholder market loop, 200–201
Sinclair C5 electric car, 197
Single-point estimates of duration, 130
Small organizations. See also Start-up companies
decision making in, 29–30
entrepreneurial mind-set of, 22–23
management focus of attention and, 22
managing new drug pipeline in, 37
meetings and, 23
P3M capability and, 266–267
portfolio management and, 11, 25
project management advantages and, 31–32
project management disadvantages and, 32
SMC. See Scottish Medicines Consortium (SMC)
Social responsibility, program strategies and, 195
Society, drug value and, 201
Software
architecture considerations, 279–280
connection between software capability and organizational P3M, 279
enterprise-wide P3M, 278–279
outsourced supplier selection criteria, 280–281
P3M capability, 278–282
project control, 126–127
Software Engineering Institute (SEI), CMMI Development Version 1.2, 288
SOPs. See Standard operating procedures (SOPs)
Specifications, 112–113
detailed, 113
performance, 112
SPI. See Schedule performance index (SPI)
Sponsorship of programs vs. projects, 88–89
Staff, achieving best practice and, 303
Stage-gate committee, 193–194
Stage-gate decision-making, 184, 185, 193–194
Stage gates, 184, 185
objectives of, 193
Stakeholder management, 89–90
best practice, 291
Stakeholders’ perception of drug value, 198, 203–215
health-care providers (doctors), 204–208
patients, 208–213
payers, 213–215
Standard operating procedures (SOPs), 43
STAR software, 231, 232, 236
Start-up companies
capacity management in, 43–44
decision-making in, 39–40
heavyweight team models and, 247
managing new drug pipeline in, 37–39
organizational leadership in, 33–36
project management in, 40–43, 46
role of project management in, 41–43
Stevens-Johnson Syndrome, 159
Stewart-Long, Pauline, 50
Strategic alignment, 56
Strategic business needs, balancing short- and long-term, 13
Strategic Decision Method, 30–31
Strategic drivers, 190–191
Strategic fit, measuring, 80
Strategic objectives, 190–191
Strategic options, 181, 182
Strategic plans, functions of, 180
Strategic thinking, 196
Strategy
business unit/therapy/disease area, 177
for change, 307
classic model, 178
corporate, 177, 185
defined, 176–178
deliberate, 177
emergent, 177
portfolio, 185
sources of, 177
Strategy definition, 250
Strategy integration, best practices, 291–293, 301
Strategy statement, 61
Structure
change program, 307
cost breakdown, 118
deliverables breakdown, 115
matrix, 25, 26, 39
organizational, 25–27
organizational breakdown, 116–117, 118
product breakdown, 115, 118
program, 90–92
work breakdown, 31, 105, 115, 116, 118

Student, 217
Sulfanilamide, 163
Sulfonamides, history of, 162–163
Supply chain management, 297
SWOT analysis, 178–179, 181
System functionality, to support new processes, 304–305
Systems
P3M capability and, 266, 272, 274–275, 277, 281, 283
P3M software, 263–264
Systems development, 4
Systems engineering, 123
Systems Engineering sector, 28

TA. See under Therapeutic area (TA);
Therapy area (TA)
Target product profile (TPP), 110–111, 113–115, 146, 296
alternative strategies and, 191, 193
development strategy and, 8
Taylor, Fredrick, 287
Teams. See also Project teams
drug development core, 27
ground rules for, 95
Technical problems, 7
Technical processes, 304
Technical risks, 76
Technical specifications, 109
Tegaserod maleate, 210–211
TGA, 161
Thalidomide, 162, 163
Theory of constraints, 130
Therapeutic area (TA) development boards, 90
Therapeutic area (TA) discovery boards, 90
Therapeutic area (TA) lines, P3M capability and, 269–270
Therapy area (TA), 55
Therapy area (TA) portfolio, 55
Therapy/disease area strategy, 177
Three-point estimating, 118
Time
development, 8
estimating work package, 117–118
in iron triangle, 75, 105
in project objective, 109
value-directed project management and,
220
Time buffers, 130
Time sensitivity of investment, 190
Time to market, 106
Timing, for developing program strategies, 183
Timing of launch, 77
Tools
capacity management, 44
program management, 97–98
Tornado diagram, 221, 222
Toxicology studies, 78
TPP. See Target product profile (TPP)
Trade-offs, project constraints and, 15
Tragedy of the Commons, 253–254, 255
Tranches, 307–308
Triptans (Imigran), 199

UMAPs. See Uncertainty Management Action Plans (UMAPs)
Uncertainty, 50–51, 137–139
defined, 137
product (drug safety), 54
program, 54
program strategy and, 179, 180
project, 54
reduction of, in R&D projects, 9
risk vs., 137
sources of, 139, 140
Uncertainty management, 56, 292–293
assigning risk and opportunity owners, 148
communicating uncertainty, 151–153
defined, 54, 55, 135–136
developing and implementing UMAPS, 148–151
identifying risks and opportunities, 141–143
in life sciences, 139–151
monitoring ongoing risk profile, 151
overview, 136–139
process cycle, 141
scoring and prioritizing, 143–148
timing of process steps, 142
Uncertainty Management Action Plans
(UMAPS), developing and implementing, 148–151
Uncertainty Register, 142–143, 144–145, 152
Uncertain uncertainty, 120
Value. See also Value management
added, 189, 202–203
assessing and managing project, 72–75
consumer, 198
drug development life cycle and, 240–243
factors with potential to impact product, 76–77
investor, 198
life-cycle management and, 240–243
measuring commercial, 189, 190
organizational meaning of, 189
perspectives on how delivered, 198
portfolio management and, 249
understanding, 221–222
Value-added activities, 43
Value-based pricing, 215–218
Value creation, 199–203
Value-directed project management, 219–221
Value engineering, 49
Value management, 12–13, 55, 56. See also
Project value management
defined, 54
Value management plan, 75
Value propositions, strategy development and, 189–190
Ventolin, 87, 88
Ventures, 246
Vertical boundaries, reshaping in integrated organization, 254
Viagra, 77
Vioxx, 157, 165–166
Vision, organizational, 194
Vocabulary, for portfolio, program, and project management, 291
Watkins, Harold Cole, 163
WBS. See Work breakdown structure (WBS)
Welch, Jack, 254
Williamson, P. M., 206
Willis, Thomas, 207
Work breakdown structure (WBS), 31, 105, 115, 116, 118
Work packages, 103, 249
defining, 115–117
estimating cost, 117–118
estimating time, 117–118
measuring progress, 125
scheduling, 118–119
Wyeth Pharmaceuticals, 157